94 related articles for article (PubMed ID: 25558698)
21. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
[TBL] [Abstract][Full Text] [Related]
22. Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma.
Leitao MM; Soslow RA; Nonaka D; Olshen AB; Aghajanian C; Sabbatini P; Dupont J; Hensley M; Sonoda Y; Barakat RR; Anderson S
Cancer; 2004 Sep; 101(6):1455-62. PubMed ID: 15316901
[TBL] [Abstract][Full Text] [Related]
23. Primary and secondary leiomyosarcoma of the oral and perioral region--clinicopathological and immunohistochemical analysis of a rare entity with a review of the literature.
Schütz A; Smeets R; Driemel O; Hakim SG; Kosmehl H; Hanken H; Kolk A
J Oral Maxillofac Surg; 2013 Jun; 71(6):1132-42. PubMed ID: 23434173
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of elevated preoperative serum CA125 in ovarian tumors of low malignant potential: a multinational collaborative study (ANZGOG0801).
Tang A; Kondalsamy-Chennakesavan S; Ngan H; Zusterzeel P; Quinn M; Carter J; Leung Y; Obermair A
Gynecol Oncol; 2012 Jul; 126(1):36-40. PubMed ID: 22370601
[TBL] [Abstract][Full Text] [Related]
25. Massive myxoid leiomyosarcoma of the uterus.
Vigone A; Giana M; Surico D; Leutner M; Surico N
Int J Gynecol Cancer; 2005; 15(3):564-7. PubMed ID: 15882188
[TBL] [Abstract][Full Text] [Related]
26. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma.
Sorak M; Arsenijević S; Lukić G; Arsenijević N; Ristić P; Pavlović S; Popović S; Baskić D
J BUON; 2007; 12(1):99-104. PubMed ID: 17436409
[TBL] [Abstract][Full Text] [Related]
27. Treatment of uterine leiomyosarcoma.
Berchuck A; Rubin SC; Hoskins WJ; Saigo PE; Pierce VK; Lewis JL
Obstet Gynecol; 1988 Jun; 71(6 Pt 1):845-50. PubMed ID: 2453004
[TBL] [Abstract][Full Text] [Related]
28. [Leiomyosarcoma of the uterus--a clinicopathologic analysis of 11 cases].
He WC
Zhonghua Zhong Liu Za Zhi; 1990 Nov; 12(6):444-6. PubMed ID: 2076642
[TBL] [Abstract][Full Text] [Related]
29. B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression.
Simon I; Katsaros D; Rigault de la Longrais I; Massobrio M; Scorilas A; Kim NW; Sarno MJ; Wolfert RL; Diamandis EP
Gynecol Oncol; 2007 Aug; 106(2):334-41. PubMed ID: 17498784
[TBL] [Abstract][Full Text] [Related]
30. [Uterine sarcomas: clinical and histopathological aspects. Report on 15 cases].
Leung F; Terzibachian JJ; Aouar Z; Govyadovskiy A; Lassabe C
Gynecol Obstet Fertil; 2008 Jun; 36(6):628-35. PubMed ID: 18538624
[TBL] [Abstract][Full Text] [Related]
31. Ovarian vein vs peripheral blood CA125 serum levels: a comparative study.
Podnos YD; Gamboa G; Kurosaki T; Buller R; Walker JL; Manetta A
Gynecol Oncol; 1997 Jul; 66(1):71-4. PubMed ID: 9234924
[TBL] [Abstract][Full Text] [Related]
32. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited.
Ma S; Shen L; Qian N; Chen K
Cancer Biomark; 2011-2012; 10(3-4):155-62. PubMed ID: 22674301
[TBL] [Abstract][Full Text] [Related]
33. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.
Kang WD; Choi HS; Kim SM
Gynecol Oncol; 2010 Jan; 116(1):57-60. PubMed ID: 19818996
[TBL] [Abstract][Full Text] [Related]
34. Immunohistological analysis of stress-induced phosphoprotein 1 in ovarian cancer patients with low serum cancer antigen 125 levels.
Chao A; Lee LY; Hsueh C; Lin CY; Tsai CL; Chao AS; Lin CT; Chou HH; Chang TC; Wang TH
Taiwan J Obstet Gynecol; 2013 Jun; 52(2):185-91. PubMed ID: 23915849
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma.
Leitao MM; Hensley ML; Barakat RR; Aghajanian C; Gardner GJ; Jewell EL; O'Cearbhaill R; Soslow RA
Gynecol Oncol; 2012 Mar; 124(3):558-62. PubMed ID: 22085894
[TBL] [Abstract][Full Text] [Related]
36. Cluster analysis of immunohistochemical markers in leiomyosarcoma delineates specific anatomic and gender subgroups.
Carvalho JC; Thomas DG; Lucas DR
Cancer; 2009 Sep; 115(18):4186-95. PubMed ID: 19626649
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients.
Mancari R; Signorelli M; Gadducci A; Carinelli S; De Ponti E; Sesana S; Corso S; Chiappa V; Colombo N; Lissoni AA
Gynecol Oncol; 2014 Jun; 133(3):531-6. PubMed ID: 24631454
[TBL] [Abstract][Full Text] [Related]
38. Prognostic factors and outcomes in 28 cases of uterine leiomyosarcoma.
Loizzi V; Cormio G; Nestola D; Falagario M; Surgo A; Camporeale A; Putignano G; Selvaggi L
Oncology; 2011; 81(2):91-7. PubMed ID: 21968290
[TBL] [Abstract][Full Text] [Related]
39. CD147 expression in uterine smooth muscle tumors, and its potential role as a diagnostic and prognostic marker in patients with leiomyosarcoma.
Ozler A; Evsen MS; Turgut A; Sak ME; Tunc SY; Agacayak E; Alabalik U; Basaranoglu S; Keles AN; Gul T
J Exp Ther Oncol; 2014; 10(4):325-30. PubMed ID: 25509988
[TBL] [Abstract][Full Text] [Related]
40. [The clinical value of tissue polypeptide antigen in ovarian carcinoma].
Wu L; Sun J; Wang X
Zhonghua Fu Chan Ke Za Zhi; 1998 Feb; 33(2):92-4. PubMed ID: 10682428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
